Author:
Lekbaby Bouchra,Vaquero Javier,Pavy Allan,Minini Mirko,Gonzalez-Sanchez Ester,Augustin Jérémy,Fouassier Laura
Reference6 articles.
1. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557–588
2. Lamarca A, Edeline J, Goyal L (2022) How I treat biliary tract cancer. ESMO Open 7:100378
3. Hudd C, Euhus DM, LaRegina MC, Herbold DR, Palmer DC, Johnson FE (1985) Effect of cholecystokinin on human cholangiocarcinoma xenografted into nude mice. Cancer Res 45:1372–1377
4. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W et al (1985) Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1:579–596
5. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H (1989) A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 25:503–510